ANDA 211451, held by Hikma Pharmaceuticals. Dexamethasone Sodium Phosphate.
As of Nov 20, 2026, ANDA 211451 (Dexamethasone Sodium Phosphate), held by Hikma Pharmaceuticals, was first approved by FDA on Aug 1, 2023, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 1, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 4MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Discontinued |
| Jun 5, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 1, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters